Search Results 1181-1190 of 11252 for Antifungal Resistance
Prior administration of genetically modified investigational live bacterial/fungal/bacteriophage/viral isolates for CDI-associated diarrhea (Exception ...
About this study. This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in ...
* Patient who are receiving concomitant medications that are strong inducers or inhibitors of CYP3A4 (with the exception of azole antifungals) and CYP2C9 that ...
... fungal-free survival at Day 90 (±7 days). The primary objective of the European Medicines Agency (EMA) for this study is to demonstrate superiority in ...
Patients must have radioactive iodine (RAI)-refractory/resistant disease as defined by one or more of the following criteria: One or more measurable lesions ...
About this study. The purpose of this study is investigate the incidence of recurrence of C. difficile infection over 8 weeks following standard of care ...
Patients with a pre-existing resistance mutation to an approved line of therapy are eligible. For example, imatinib resistant mutations including KIT Exon 17 ...
Subjects with active infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week ...
No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections;; A CD4 count above 250 cells/mcL and an ...
This research study is being done to create a collection of biospecimens (blood, urine, cyst fluid, bile, kidney or liver tissue, etc.) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.